Please tell us about your clinical experience. How many patients with melanoma do you see, yearly?

What treatment has seen the best results and why? How could lifileucel or ITIL-168 fit in this space?

Can you tell us more about the field of tumor-infiltrating lymphocytes in cancer cell therapy, considering the oldest successful treatment using this method dates to 1988?

Can we talk about Instill’s results between 2011-2019, where,according to the IPO filing, of the 21 patients treated under compassionate use, 4 showed complete remission of their cancers. Partial remission was observed in 10. Instil said that four patients reported stable disease. A total of 10 patients have since died from complications that arose as their disease progressed.

Instil Bio says that the challenge of manufacturing TIL therapy has limited its use. Where do you see a potential breakthrough in this area, considering that Instil will spend $150m to develop its proprietary process to cryopreserve surgically removed tissue at a regional hub close to a clinical site, shipping samples to one of two Instil manufacturing sites, in Manchester and Los Angeles.

What can you tell us about Iovance’s Gen2 TIL expansion protocol, as it relates to the manufacturing ? In one of its abstracts, the company cites the process to last 22-days.

How likely would you be to switch your patients to either of those 2 therapies, in the future. Which one would you be inclined to use more, and why?

In a meta-analysis of TIL therapies between 1988-2016, data shows an ORR of 41% and a CR rate of 12% in 410 heavily pretreated patients with metastatic melanoma, withone of 28 patients experiencing disease recurrence. How does this compare to standard of care?